Local control and complications after radiation therapy for primary orbital lymphoma: A case for low-dose treatment

Kern J. Minehan, James A. Martenson, James A. Garrity, Paul J. Kurtin, Peter M. Banks, Michael G. Chen, John D. Earle

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Orbital involvement at the time of initial presentation is unusual in non-Hodgkin's lymphoma. In an effort to identify potential ways of improving the radiotherapeutic management of this disease, the records of 22 patients were reviewed retrospectively. All had biopsy-proven orbital non-Hodgkin's lymphoma, and the minimal, median, and maximal durations of follow-up in surviving patients were 4.8 years, 7.0 years, and 17.4 years, respectively. Permanent local control was achieved in 21 of the 22 patients (96%). Complications were scored according to a grading scheme in which grade 1 was the least significant complication and grade 4 was blindness as a result of radiation therapy. Of the 12 patients who received a radiation dose < 35 Gy, 6 developed a grade 1 or grade 2 complication. Of the 10 patients treated with ≥35 Gy, 6 experienced a complication, 1 of whom had a grade 4 complication resulting in blindness and another who developed a severe keratitis, which was scored as a grade 3 complication resulting in decreased visual acuity. At last follow-up, 10 patients were alive at 4.8 to 17.4 years after completion of radiation therapy, 4 had died of intercurrent disease at 3 months to 10.6 years, and 8 had died of disease at 3 months to 15.8 years. Actuarial survival for the entire group was 75% at 5 years and 48% at 10 years. Survival in patients with Stage I AE disease (lymphoma confined to orbit) at presentation was 87% at 5 years and 50% at 10 years, and survival in patients with Stage II A through Stage IV disease was 36% at 5 years and at 10 years. Primary orbital lymphoma is an indolent disease characterized by prolonged survival after radiation therapy. Excellent local control can be achieved with radiation doses of 20 Gy to 35 Gy. Higher doses may result in an increased risk of complications.

Original languageEnglish (US)
Pages (from-to)791-796
Number of pages6
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume20
Issue number4
DOIs
StatePublished - 1991

Fingerprint

radiation therapy
Radiotherapy
orbitals
grade
dosage
blindness
Survival
Blindness
Therapeutics
Non-Hodgkin's Lymphoma
keratitis
Forms and Records Control
visual acuity
Radiation
Orbital lymphoma
Keratitis
Orbit
radiation
Disease Management
Visual Acuity

Keywords

  • Complications
  • Non-Hodgkin's lymphoma
  • Orbit
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Local control and complications after radiation therapy for primary orbital lymphoma : A case for low-dose treatment. / Minehan, Kern J.; Martenson, James A.; Garrity, James A.; Kurtin, Paul J.; Banks, Peter M.; Chen, Michael G.; Earle, John D.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 20, No. 4, 1991, p. 791-796.

Research output: Contribution to journalArticle

Minehan, Kern J. ; Martenson, James A. ; Garrity, James A. ; Kurtin, Paul J. ; Banks, Peter M. ; Chen, Michael G. ; Earle, John D. / Local control and complications after radiation therapy for primary orbital lymphoma : A case for low-dose treatment. In: International Journal of Radiation Oncology, Biology, Physics. 1991 ; Vol. 20, No. 4. pp. 791-796.
@article{fb2f6b8416ea4182b8d3304c6a8c6c3b,
title = "Local control and complications after radiation therapy for primary orbital lymphoma: A case for low-dose treatment",
abstract = "Orbital involvement at the time of initial presentation is unusual in non-Hodgkin's lymphoma. In an effort to identify potential ways of improving the radiotherapeutic management of this disease, the records of 22 patients were reviewed retrospectively. All had biopsy-proven orbital non-Hodgkin's lymphoma, and the minimal, median, and maximal durations of follow-up in surviving patients were 4.8 years, 7.0 years, and 17.4 years, respectively. Permanent local control was achieved in 21 of the 22 patients (96{\%}). Complications were scored according to a grading scheme in which grade 1 was the least significant complication and grade 4 was blindness as a result of radiation therapy. Of the 12 patients who received a radiation dose < 35 Gy, 6 developed a grade 1 or grade 2 complication. Of the 10 patients treated with ≥35 Gy, 6 experienced a complication, 1 of whom had a grade 4 complication resulting in blindness and another who developed a severe keratitis, which was scored as a grade 3 complication resulting in decreased visual acuity. At last follow-up, 10 patients were alive at 4.8 to 17.4 years after completion of radiation therapy, 4 had died of intercurrent disease at 3 months to 10.6 years, and 8 had died of disease at 3 months to 15.8 years. Actuarial survival for the entire group was 75{\%} at 5 years and 48{\%} at 10 years. Survival in patients with Stage I AE disease (lymphoma confined to orbit) at presentation was 87{\%} at 5 years and 50{\%} at 10 years, and survival in patients with Stage II A through Stage IV disease was 36{\%} at 5 years and at 10 years. Primary orbital lymphoma is an indolent disease characterized by prolonged survival after radiation therapy. Excellent local control can be achieved with radiation doses of 20 Gy to 35 Gy. Higher doses may result in an increased risk of complications.",
keywords = "Complications, Non-Hodgkin's lymphoma, Orbit, Radiation therapy",
author = "Minehan, {Kern J.} and Martenson, {James A.} and Garrity, {James A.} and Kurtin, {Paul J.} and Banks, {Peter M.} and Chen, {Michael G.} and Earle, {John D.}",
year = "1991",
doi = "10.1016/0360-3016(91)90025-Y",
language = "English (US)",
volume = "20",
pages = "791--796",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Local control and complications after radiation therapy for primary orbital lymphoma

T2 - A case for low-dose treatment

AU - Minehan, Kern J.

AU - Martenson, James A.

AU - Garrity, James A.

AU - Kurtin, Paul J.

AU - Banks, Peter M.

AU - Chen, Michael G.

AU - Earle, John D.

PY - 1991

Y1 - 1991

N2 - Orbital involvement at the time of initial presentation is unusual in non-Hodgkin's lymphoma. In an effort to identify potential ways of improving the radiotherapeutic management of this disease, the records of 22 patients were reviewed retrospectively. All had biopsy-proven orbital non-Hodgkin's lymphoma, and the minimal, median, and maximal durations of follow-up in surviving patients were 4.8 years, 7.0 years, and 17.4 years, respectively. Permanent local control was achieved in 21 of the 22 patients (96%). Complications were scored according to a grading scheme in which grade 1 was the least significant complication and grade 4 was blindness as a result of radiation therapy. Of the 12 patients who received a radiation dose < 35 Gy, 6 developed a grade 1 or grade 2 complication. Of the 10 patients treated with ≥35 Gy, 6 experienced a complication, 1 of whom had a grade 4 complication resulting in blindness and another who developed a severe keratitis, which was scored as a grade 3 complication resulting in decreased visual acuity. At last follow-up, 10 patients were alive at 4.8 to 17.4 years after completion of radiation therapy, 4 had died of intercurrent disease at 3 months to 10.6 years, and 8 had died of disease at 3 months to 15.8 years. Actuarial survival for the entire group was 75% at 5 years and 48% at 10 years. Survival in patients with Stage I AE disease (lymphoma confined to orbit) at presentation was 87% at 5 years and 50% at 10 years, and survival in patients with Stage II A through Stage IV disease was 36% at 5 years and at 10 years. Primary orbital lymphoma is an indolent disease characterized by prolonged survival after radiation therapy. Excellent local control can be achieved with radiation doses of 20 Gy to 35 Gy. Higher doses may result in an increased risk of complications.

AB - Orbital involvement at the time of initial presentation is unusual in non-Hodgkin's lymphoma. In an effort to identify potential ways of improving the radiotherapeutic management of this disease, the records of 22 patients were reviewed retrospectively. All had biopsy-proven orbital non-Hodgkin's lymphoma, and the minimal, median, and maximal durations of follow-up in surviving patients were 4.8 years, 7.0 years, and 17.4 years, respectively. Permanent local control was achieved in 21 of the 22 patients (96%). Complications were scored according to a grading scheme in which grade 1 was the least significant complication and grade 4 was blindness as a result of radiation therapy. Of the 12 patients who received a radiation dose < 35 Gy, 6 developed a grade 1 or grade 2 complication. Of the 10 patients treated with ≥35 Gy, 6 experienced a complication, 1 of whom had a grade 4 complication resulting in blindness and another who developed a severe keratitis, which was scored as a grade 3 complication resulting in decreased visual acuity. At last follow-up, 10 patients were alive at 4.8 to 17.4 years after completion of radiation therapy, 4 had died of intercurrent disease at 3 months to 10.6 years, and 8 had died of disease at 3 months to 15.8 years. Actuarial survival for the entire group was 75% at 5 years and 48% at 10 years. Survival in patients with Stage I AE disease (lymphoma confined to orbit) at presentation was 87% at 5 years and 50% at 10 years, and survival in patients with Stage II A through Stage IV disease was 36% at 5 years and at 10 years. Primary orbital lymphoma is an indolent disease characterized by prolonged survival after radiation therapy. Excellent local control can be achieved with radiation doses of 20 Gy to 35 Gy. Higher doses may result in an increased risk of complications.

KW - Complications

KW - Non-Hodgkin's lymphoma

KW - Orbit

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0025911241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025911241&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(91)90025-Y

DO - 10.1016/0360-3016(91)90025-Y

M3 - Article

C2 - 2004956

AN - SCOPUS:0025911241

VL - 20

SP - 791

EP - 796

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -